Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Business Wire•22/10/2026•16:11 ET
0
Key Highlights
- ➤Puma will release third quarter 2026 financial results before November 5 conference call
- ➤Puma initiated ALISCA-Lung2 Phase II trial in September 2026
- ➤ALISCA-Lung1 Phase II trial evaluates alisertib monotherapy in extensive-stage small cell lung cancer
- ➤ALISCA-Breast1 Phase II trial evaluates alisertib with endocrine therapy in HER2-negative metastatic breast cancer
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results.
Get started
Create a free account to read the full story.